Teva Pharmaceutical Industries Limited
TEVA
$33.92
-$0.39-1.14%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 185.97% | 174.24% | 65.12% | -168.48% | -192.68% |
| Total Depreciation and Amortization | -5.19% | -4.07% | -5.28% | -8.03% | -8.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -73.30% | -28.61% | 51.48% | 123.27% | 167.06% |
| Change in Net Operating Assets | -214.48% | -1,905.88% | -118.10% | -190.00% | -504.17% |
| Cash from Operations | 32.24% | -42.56% | 19.01% | -8.86% | -8.85% |
| Capital Expenditure | -0.60% | 0.00% | -2.25% | 1.96% | 5.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 100.00% | 100.00% | 100.00% | -- |
| Divestitures | -20.93% | -2.56% | 518.18% | -9.09% | -36.76% |
| Other Investing Activities | -4.60% | -9.67% | 3.00% | -7.26% | -11.50% |
| Cash from Investing | -6.94% | -13.13% | 12.39% | -8.81% | -18.18% |
| Total Debt Issued | -- | -- | 229.29% | -- | -- |
| Total Debt Repaid | -151.01% | -229.95% | -63.89% | -77.00% | 66.18% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -124.67% | -54.43% | -16.29% | -4.75% | 29.25% |
| Cash from Financing | -20.10% | -69.23% | -6.30% | -149.19% | 6.38% |
| Foreign Exchange rate Adjustments | 112.07% | -700.00% | 116.10% | 82.88% | -480.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | 200.00% | -- |
| Net Change in Cash | 245.95% | -204.30% | 76.70% | -258.65% | -81.17% |